The treatment of lung cancer is rapidly evolving.  Minimally invasive surgical techniques are shifting towards robotics and more limited anatomic lung resections while medical therapies have expanded with immunotherapy and targeted therapy.  Until recently, new systemic therapies were mostly evaluated in the metastatic setting, but there have been several recent studies in resectable lung cancer that have shown impressive clinical outcomes.  At this meeting we hope to provide a detailed analysis of the clinical studies, and provoke a robust discussion regarding the multi-disciplinary care of these patients, in hopes of improving outcomes for NSCLC patients in the Spokane region.